Diabetes

Omega-3 fatty acid supplements may help address the growing prevalence of type 2 diabetes mellitus and diabetic retinopathy.

Sanofi has submitted updated information to the FDA as part of a previously submitted New Drug Application (NDA) for its investigational once-daily, fixed-ratio combination of basal insulin glargine 100 units/mL (Lantus) and lixisenatide (Adlyxin) to treat type 2 diabetes in adults.

Research advances work towards targeted therapies for type 2 diabetes.

SGLT2 inhibitors can lower blood glucose levels and potentially protect the kidneys.

Regenerative bandage could reduce amputations and poor health outcomes from diabetic sores.

One of the most frequent questions patients ask is, Can I travel with my medications?"

Flavanone consumption associated with lower levels of cell-damage markers.

Prescribed diabetes therapies may be leading to reduced kidney function.

Observing retinal changes and treating patients with an anti-diabetic drug could protect against Parkinson’s disease progression.

Roche recently launched an innovative blood glucose monitoring system designed to simplify everyday diabetes management with features like a spill-resistant test strip vial.

Mice treated with linagliptin gained weight, but did not experience aortic stiffness.

Newly found protein sheds light on insulin resistance and type 2 diabetes.

Although it was previously found that kidney disease can cause diabetes, the diseases also have an inverse relationship.

Sedentary behavior can lead to cardiovascular disease, and in turn, diabetic retinopathy.

The FDA has approved Basaglar, a long-acting human insulin analog, to improve glycemic control in adults and children with type 1 diabetes and in adults with type 2 diabetes.

Recently, researchers identified 5 predictive factors for weight loss extent in overweight patients with type 2 diabetes.

Early diagnosis and management of ketoacidosis is vital.

Pharmacy medication synchronization programs may simplify care for diabetes and other chronic conditions.

Targeting early marker of insulin resistance shows promise in type 2 diabetes.

New therapies on the horizon for cancer, multiple sclerosis, and rheumatoid arthritis.

Top news of the day from across the health care landscape.

When fat tissue becomes altered, the likelihood of inflammation and metabolic disorders increases.

A small proportion of patients with autoimmune syndrome have diabetes.

Statin therapy not found to cause diabetes among patients with low levels of LDL cholesterol.

Pokémon Go may help reduce burdens of obesity and diabetes.